BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tartour E, Mehtali M, Sastre-Garau X, Joyeux I, Mathiot C, Pleau JM, Squiban P, Rochlitz C, Courtney M, Jantscheff P. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br J Cancer. 2000;83:1454-1461. [PMID: 11076653 DOI: 10.1054/bjoc.2000.1492] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu T, Kirn DH. Problems, Side Effects, and Disappointments in Clinical Cancer Gene Therapy. In: Hunt KK, Vorburger SA, Swisher SG, editors. Gene Therapy for Cancer. Totowa: Humana Press; 2007. pp. 351-85. [DOI: 10.1007/978-1-59745-222-9_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Dueñas-gonzalez A, Verastegui E, Lopez-graniel C, Gonzalez A, Mota A, Barrera-franco J, Meneses A, Chanona J, de la Garza J, Chavez-blanco A, Hadden J. A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma: preliminary report. International Immunopharmacology 2002;2:1007-16. [DOI: 10.1016/s1567-5769(02)00048-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Jas D, Soyer C, De Fornel-thibaud P, Oberli F, Vernes D, Guigal P, Poulet H, Devauchelle P. Adjuvant immunotherapy of feline injection-site sarcomas with the recombinant canarypox virus expressing feline interleukine-2 evaluated in a controlled monocentric clinical trial when used in association with surgery and brachytherapy. Trials in Vaccinology 2015;4:1-8. [DOI: 10.1016/j.trivac.2014.11.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yesilada E, Bedir E, Caliş I, Takaishi Y, Ohmoto Y. Effects of triterpene saponins from Astragalus species on in vitro cytokine release. J Ethnopharmacol 2005;96:71-7. [PMID: 15588652 DOI: 10.1016/j.jep.2004.08.036] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 6.7] [Reference Citation Analysis]
5 Mukherjee S, Upham JW, Ramshaw I, Bundell C, van Bruggen I, Robinson BW, Nelson DJ. Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12. Cancer Gene Ther 2003;10:591-602. [DOI: 10.1038/sj.cgt.7700604] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
6 Xu CT, Huang LT, Pan BR. Current gene therapy for stomach carcinoma. World J Gastroenterol 2001; 7(6): 752-759 [PMID: 11819868 DOI: 10.3748/wjg.v7.i6.752] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
7 Liu L, Wang S, Shan B, Sang M, Liu S, Wang G. Advances in viral-vector systemic cytokine gene therapy against cancer. Vaccine 2010;28:3883-7. [PMID: 20371389 DOI: 10.1016/j.vaccine.2010.03.041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
8 Minuzzo S, Moserle L, Indraccolo S, Amadori A. Angiogenesis meets immunology: Cytokine gene therapy of cancer. Molecular Aspects of Medicine 2007;28:59-86. [DOI: 10.1016/j.mam.2006.12.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sloot S, Rashid OM, Sarnaik AA, Zager JS. Developments in Intralesional Therapy for Metastatic Melanoma. Cancer Control 2016;23:12-20. [PMID: 27009452 DOI: 10.1177/107327481602300104] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
10 Hofbauer GF, Baur T, Bonnet MC, Tartour E, Burg G, Berinstein NL, Dummer R. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res 2008;18:104-11. [PMID: 18337646 DOI: 10.1097/CMR.0b013e3282f702cf] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
11 Power AT, Bell JC. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 2007;15:660-5. [PMID: 17264852 DOI: 10.1038/sj.mt.6300098] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 4.2] [Reference Citation Analysis]
12 Tan PH, Chan CLH, Chan C, George AJT. The evolving role of gene-based treatment in surgery. British Journal of Surgery 2005;92:1466-80. [DOI: 10.1002/bjs.5181] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
13 Schadendorf D. Gene-based therapy of malignant melanoma. Seminars in Oncology 2002;29:503-12. [DOI: 10.1053/sonc.2002.35245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
14 Sloot S, Rashid OM, Zager JS. Intralesional therapy for metastatic melanoma. Expert Opin Pharmacother 2014;15:2629-39. [PMID: 25381015 DOI: 10.1517/14656566.2014.967682] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
15 Nelson DJ, Robinson BW, Allan J, van der Most R. Gene therapy of mesothelioma. Expert Opinion on Biological Therapy 2005;5:1039-49. [DOI: 10.1517/14712598.5.8.1039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
16 Rochlitz C, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B, Baudin M, Escudier B, Heinzerling L, Morant R, Herrmann R, Dietrich PY, Dummer R. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 2002;9:289-95. [PMID: 11896446 DOI: 10.1038/sj.cgt.7700441] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
17 Samlowski WE, Mcgregor JR, Jurek M, Baudys M, Zentner GM, Fowers KD. ReGel® Polymer-based Delivery of Interleukin-2 as a Cancer Treatment. Journal of Immunotherapy 2006;29:524-35. [DOI: 10.1097/01.cji.0000211306.05869.25] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
18 Gey A, Kumari P, Sambandam A, Lecuru F, Cassard L, Badoual C, Fridman C, Nagarajan B, Fridman WH, Tartour E. Identification and characterisation of a group of cervical carcinoma patients with profound downregulation of intratumoral Type 1 (IFNgamma) and Type 2 (IL-4) cytokine mRNA expression. Eur J Cancer 2003;39:595-603. [PMID: 12628838 DOI: 10.1016/s0959-8049(02)00839-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]